Larimar Therapeutics, Inc.
NASDAQ:LRMRBiotechnology
+$0.04 today
- Market cap
- $310.61M
- Beta
- 0.82
- P/E (TTM)
- -1.8
- EPS (TTM)
- -$1.95
Volume 1.38M
Average 1.73M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
Larimar Therapeutics, Inc.
NASDAQ:LRMR
Intrinsic Alpha fair value
Locked
Current Price
$2.99
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | N/A6 analysts |
| Net Income | N/A | N/A | N/A | N/A6 analysts |
| EBIT | N/A | N/A | N/A | N/A6 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
Alto Neuroscience, Inc. NYSE:ANRO | $1.18B | $29.54 | Not rated | -9.8 | +68.88% |
Annexon, Inc. NASDAQ:ANNX | $642.26M | $3.92 | Not rated | -4.8 | +8.44% |
Altimmune, Inc. NASDAQ:ALT | $319.98M | $1.65 | Not rated | -3.7 | -67.10% |
Kyverna Therapeutics, Inc. NASDAQ:KYTX | $312.31M | $5.05 | Not rated | -3.1 | -39.97% |
DBV Technologies S.A. NASDAQ:DBVT | $263.50M | $11.02 | Not rated | -8.3 | -28.28% |
Lexeo Therapeutics, Inc. Common Stock NASDAQ:LXEO | $235.59M | $2.87 | Not rated | -4.6 | -68.90% |
Amarin Corporation plc NASDAQ:AMRN | $235.37M | $11.38 | Not rated | -9.9 | -32.56% |
AC Immune S.A. NASDAQ:ACIU | $216.78M | $2.13 | Not rated | -2.9 | -30.82% |
Korro Bio, Inc. NASDAQ:KRRO | $196.29M | $13.61 | Not rated | -1.3 | +98.07% |
enGene Holdings Inc. NASDAQ:ENGN | $161.51M | $2.41 | Not rated | -1.8 | -75.00% |
Continue the stock analysis
Jump to another research area for this company.